(617 days)
The EasyStat 300 is designed for clinical laboratory use, making quantitative measurements of pO2 (partial pressure of oxygen), pCO2 (partial pressure of carbon dioxide), and pH (hydrogen ion activity) in whole blood (arterial/venous) samples from Li-Heparinized Syringes or Capillary Tubes. This Analyzer should only be used by trained technicians in clinical laboratories to aid in the diagnosis and treatment of patients with blood gas and/or acid-base disturbances.
Blood gases (p02, pCO2) and pH measurements in blood are used in the diagnosis and treatment of life-threatening acidbase disturbances.
The EasyStat 300 is a system for use by health care professionals to rapidly analyze whole blood samples. The analyzer incorporates a Reagent Module containing the "calibrating" solutions A2, B2, and a "conditioning" solution C2, which is also use a calibrant for the Oxygen sensor. Calibrations are performed automatically or on-demand by the user to establish the "slope" of each sensor used in the calculation of the patient sample. The EasyStat 300 uses 175μL of whole blood in the "Syringe" mode and 100μL of whole blood in the "Capillary" mode to analyze patient samples. The EasyStat 300 reports results for blood Gases (PCO2, PO2), and pH. Additionally, it provides a number of calculated parameters based on the reported results and a number of input parameters as described in the Operator's Manual. The EasyStat 300 is a microprocessor-controlled device with a touch sensitive screen that guides the operator through the different menu options and proper operation. It also incorporates a thermal printer to record all reported results and patient information as described in the Operator's Manual. The device software has incorporated routines to assist the end-user with maintenance, cleaning, and troubleshooting activities also outlined in the manual. The incorporated USB port may be used to download data and also to update the software version based on detailed instructions by Medica Corporation. The blood gas and pH sensors require calibration and cleaning after a predefined number of samples are analyzed as described in the Operator's Manual. The pH and PCO2 sensors are based on potentiometric sensor design, generating a small voltage that is dependent on the concentrations of these analytes in the patient sample. The PO2 sensor is based on amperometric sensor design that generates a small current that is dependent on the concentration of oxygen in the patient sample. Medica's EasyQC materials are specifically formulated for the EasyStat 300. The EasyStat 300 may be equipped with a Medica provided barcode scanner via a USB port to automatically enter patient sample and EasyQC material info. To maintain the performance of the analyzer Medica provides a cleaning solution and a troubleshooting kit.
Here's a breakdown of the acceptance criteria and the study that proves the EasyStat 300 device meets these criteria, based on the provided FDA 510(k) summary.
Key Findings from the Document:
- Device: EasyStat 300 Blood Gas Analyzer
- Purpose: Measures pO2, pCO2, and pH in whole blood.
- Comparison: Substantially equivalent to its predicate device, the EasyStat Blood Gas Analyzer (K021515).
- Studies Conducted: Precision (Repeatability, Reproducibility), Linearity, Method Comparison, Sensitivity, and Selectivity (Interference).
- Ground Truth for Analytical Studies: Primarily based on pre-assayed whole blood samples, aqueous QC materials, and tonometered whole blood, with comparisons against results from the predicate device.
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly present a single table labeled "Acceptance Criteria," but rather presents "Performance Specs" within the precision studies and "Status" (PASS) for linearity and method comparison, indicating adherence to pre-defined criteria. The interference study uses a "Conclusion" column based on a predefined percentage change. Based on the data provided, the acceptance criteria are inferred from the "Performance Specs" headers and the overall "PASS" status for each test.
| Assay Category | Acceptance Criteria (Performance Specs) | Reported Device Performance (Summary) |
|---|---|---|
| Precision | ||
| Repeatability | pO2: Level 1: 2.5 SD; Level 2: 2.5 SD; Level 3: 2.5% CV | Aqueous Controls (Syringe Mode): All results "within specification." Examples:- System 1 PO2 Level 1: 1.39 SD (vs 2.5 SD)- System 1 PCO2 Level 1: 0.9 CV (vs 5.0% CV)- System 1 pH Level 1: 0.002 SD (vs 0.020 SD)Aqueous Controls (Capillary Mode): All results "within specification." Examples:- Unit 1 PO2 Level 1: 2.70 SD (vs 3 SD)- Unit 1 PCO2 Level 1: 1.5 CV (vs 5.0% CV)- Unit 1 pH Level 1: 0.004 SD (vs 0.020 SD) |
| Reproducibility | pO2: Level 1: 2.5mmHg; Level 2: 2.5mmHg; Level 3: 3.0% CV | 5-day w. Blood Study (Syringe Mode): All results "within specification." Examples:- PO2 Level 1: 0.6 SD (vs 2.5mmHg)- PCO2 Level 1: 0.5 SD (vs 2.0% CV, implied from table structure)- pH Level 1: 0.007 SD (vs 0.015 units)5-day w. Blood Study (Capillary Mode): All results "within specification." Examples:- PO2 Level 1: 0.9 SD (vs 2.4mmHg)- PCO2 Level 1: 2.5 CV (vs 4.0% CV)- pH Level 1: 0.008 SD (vs 0.015 units) |
| Linearity | "met all device specifications" (implied criteria typically high R^2 values, slope ~1) | Data shown (e.g., for ES300-P7):- PO2 (Syringe): R² 0.999, Slope 1.016 (PASS)- PCO2 (Syringe): R² 0.999, Slope 1.066 (PASS)- pH (Syringe): R² 0.996, Slope 1.008 (PASS)Conclusion: "all analytes... are linear within the advertised reportable range." |
| Method Comparison | "linear regression slope, the coefficient of variation, and the calculated predicted bias at the decision levels for each analyte were within specifications." (implied) | Exemplified by PO2 Syringe Mode:- n=272, Slope=1.001, R²=0.999- Predicted Bias for PO2 (30.0, 45.0, 60.0): All PASS ("within specifications," typically close to 0 bias and CI within allowable error).Conclusion: "all analytes... are favorably correlated to the predicate/reference device... within specifications." |
| Sensitivity | LoQ < Lowest Detection Limit (LDL) for each analyte | All LoQ values are less than their respective LDLs.- pO2: LoQ 4 mmHg < LDL 5 mmHg (Yes)- pCO2: LoQ 4.6 mmHg < LDL 5.0 mmHg (Yes)- pH: LoQ 6.498 pH units < LDL 6.800 pH units (Yes)Conclusion: "The lower reportable limit for each assay... was based on the LoQ result... indicating that the following values may be used as the lowest limit of the reportable range... pO2: 5 mmHg; pCO2: 5.0 mmHg; pH: 6.800 units." |
| Selectivity | Change in analyte value < 10% due to interferent | All 23 tested substances (e.g., Acetaminophen, Albumin, Bilirubin, Ethanol) showed "No Interference" for pO2, pCO2, and pH across two levels (Level A and Level B), indicating changes were < 10%. |
2. Sample Size Used for the Test Set and Data Provenance
-
Test Set Sample Sizes:
- Precision (Repeatability):
- Aqueous Controls (Syringe & Capillary): 3 EasyStat 300 analyzers, 3 quality control levels, analyzed for 20 days, taking duplicate readings in the morning (AM) and afternoon (PM). This means 3 analyzers * 3 levels * 20 days * 2 readings = 360 data points per analyte.
- Precision (Reproducibility):
- Whole Blood (Syringe & Capillary): 5 replicates of whole blood for 5 days. (Implies 25 total replicates for each analyte per mode per unit, but the exact number of units is not specified for this particular study, though the previous study used 3 units).
- Linearity: 9 to 11 spiked and diluted whole blood specimens, tested in triplicate on 3 EasyStat 300 analyzers. (Yields approximately 27-33 data points per analyte per analyzer for a total of 81-99 data points per analyte).
- Method Comparison: Whole blood from "more than 200 donors," plus six modified whole blood samples. All samples were tested on the predicate devices twice and on three EasyStat 300 analyzers.
- Syringe Mode: n=272 for PO2; n=265 for PCO2; n=268 for pH.
- Capillary Mode: n=224 for PO2; n=219 for PCO2; n=216 for pH.
- Sensitivity: Performed on 3 ES 300 analyzers. The number of samples per analyzer is not explicitly stated but is typically multiple replicates of blank and low-concentration samples.
- Selectivity: The number of samples is not directly stated but involved "spiked whole blood samples collected from healthy donors" for each of the 23 interferents, tested at two "Gas/pH Levels" (A and B).
- Precision (Repeatability):
-
Data Provenance:
- The document states, "All tests on the following sections are non-clinical bench tests except for Method Comparison, which was performed on a clinical laboratory using actual venous and arterial blood."
- The non-clinical tests used "contrived venous blood of aqueous QC materials" and "tonometered w. Blood."
- Country of Origin: Not explicitly stated, but Medica Corporation is located in Bedford, MA, which suggests US origin for the company, implying the studies were likely conducted within the US or under US regulatory standards.
- Retrospective or Prospective: All studies described appear to be prospective analytical studies conducted specifically for this 510(k) submission.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
- Number of Experts: Not specified.
- Qualifications of Experts: Not specified.
- How Ground Truth Was Established (for analytical studies): The ground truth for the test sets in these analytical studies was primarily established by:
- Reference Methods/Predicate Device: For the method comparison study, samples were run on the predicate device (EasyStat analyzer) to serve as the reference.
- Pre-assayed Materials: Linearity studies used "pre-assayed whole blood samples."
- Aqueous QC Materials: Precision studies extensively used "EasyQC tri-level aqueous material" provided by Medica itself.
- Spiking/Dilution/Tonometry: Samples were manipulated (spiked, diluted, tonometered) to cover the analytical measurement range and introduce interferents, providing a controlled "ground truth" for those specific tests.
- Known Concentrations: Sensitivity studies used the known concentrations of buffered saline or tonometered blood to determine detection limits.
These are analytical performance studies, not clinical studies involving expert interpretation of images or clinical outcomes. Therefore, the concept of "experts establishing ground truth" in the diagnostic interpretation sense (e.g., radiologists for imaging) does not directly apply here. The ground truth is laboratory-based and instrument-based.
4. Adjudication Method for the Test Set
- Adjudication Method: Not applicable.
- These are analytical performance studies of a laboratory device designed to measure specific blood gas and pH values. The "test set" in this context refers to the samples run on the device, not a set of cases requiring human interpretation and multi-expert adjudication.
- The "ground truth" is established by reference methods or known concentrations, not by consensus of human experts adjudicating a clinical finding.
5. If a Multi Reader Multi Case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- MRMC Study: Not applicable.
- The EasyStat 300 is a blood gas analyzer, an in-vitro diagnostic (IVD) device that directly measures chemical parameters in blood. It is not an AI-assisted diagnostic imaging device or a system that requires human interpretation of complex data for diagnosis. Therefore, MRMC studies and concepts of human reader improvement with AI assistance are not relevant to this device.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Standalone Performance: Yes, the entire performance evaluation described in the summary is effectively a "standalone" assessment of the EasyStat 300's analytical performance capabilities. The device processes samples and generates numerical results for pO2, pCO2, and pH without human intervention in the measurement process itself, beyond sample loading and initiation. The studies evaluate the device's accuracy, precision, linearity, sensitivity, and selectivity in producing these measurements.
7. The Type of Ground Truth Used
The ground truth used for these studies includes:
- Predicate Device Measurements: For method comparison, the results from the legally marketed predicate device (EasyStat Blood Gas Analyzer) served as the reference standard.
- Pre-assayed Whole Blood Samples: Used in linearity studies, where the expected values were established prior to testing.
- Aqueous Quality Control Materials (EasyQC): Used extensively in precision studies, these materials have known target concentrations.
- Tonometered Whole Blood: Used in sensitivity studies and for modifying samples for method comparison/linearity. Gas tonometry allows for precise control of pO2 and pCO2 levels in blood.
- Buffered Saline: Used in pH sensitivity studies as a sample with a known pH.
- Spiked and Diluted Whole Blood Samples: Used to create samples with varying known concentrations or to introduce interferents for linearity and selectivity studies.
8. The Sample Size for the Training Set
- Training Set Sample Size: Not applicable / Not explicitly provided for algorithm training.
- The EasyStat 300 is an IVD device based on established potentiometric and amperometric sensor technology, not a machine learning or AI-based device that typically undergoes "training" on large datasets. Its function relies on electrochemical principles and calibration, not a trained algorithm that learns from data. Therefore, the concept of a "training set" in the machine learning sense does not apply here. The device is calibrated and validated through the analytical studies described.
9. How the Ground Truth for the Training Set Was Established
- Ground Truth for Training Set: Not applicable.
- As explained above, this device does not utilize an AI/ML algorithm that requires a "training set" with established ground truth in the way medical imaging AI models do. Its "training" involves chemical and electrical calibration procedures as part of its normal operation, based on known physical and chemical principles documented in the operator's manual. The validation of its performance relies on the analytical studies against predicate devices, reference materials, and controlled samples.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: on the left, there is a seal with an abstract design, and on the right, there is the text "FDA U.S. FOOD & DRUG ADMINISTRATION" in blue. The text is arranged in three lines, with "FDA" being the largest and boldest, followed by "U.S. FOOD & DRUG" and then "ADMINISTRATION".
January 27, 2023
Medica Corporation Photios Makris VP Regulatory Affairs 5 Oak Park Drive Bedford, MA 01730
Re: K211559
Trade/Device Name: EasyStat 300 Regulation Number: 21 CFR 862.1120 Regulation Name: Blood Gases (PCO2, PO2) and Blood pH Test System Regulatory Class: Class II Product Code: CHL Dated: September 30, 2022 Received: October 3, 2022
Dear Photios Makris:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
{1}------------------------------------------------
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Digitally signed by Paula Paula Caposino -S Caposino -S Date: 2023.01.27
12:07:22 -05'00' Paula V. Caposino, Ph.D. Acting Deputy Director
Division of Chemistry and Toxicology Devices OHT7: Office of In Vitro Diagnostics Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K211559
Device Name EasyStat 300
Indications for Use (Describe)
The EasyStat 300 is designed for clinical laboratory use, making quantitative measurements of pO2 (partial pressure of oxygen), pCO2 (partial pressure of carbon dioxide), and pH (hydrogen ion activity) in whole blood (arterial/venous) samples from Li-Heparinized Syringes or Capillary Tubes. This Analyzer should only be used by trained technicians in clinical laboratories to aid in the diagnosis and treatment of patients with blood gas and/or acid-base disturbances.
Blood gases (p02, pCO2) and pH measurements in blood are used in the diagnosis and treatment of life-threatening acidbase disturbances.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) Summary
Submitted By:
Medica Corporation 5 Oak Park Drive Bedford, MA 01730
Contact Person:
Photios Makris, VP. Regulatory Affairs Phone: 781-541-7443 Fax: 781-275-2731 pmakris@medicacorp.com E-mail:
Summary Prepared:
January 25th, 2023
| Trade Name: | EasyStat 300 |
|---|---|
| Common Name: | Blood Gas Analyzer |
| Classification Name: | Blood Gases and Blood pH Test System |
Regulatory Information:
EasyStat 300 Analyzer
| Description | Regulation No. | Device Class | Product Code |
|---|---|---|---|
| Blood Gas and blood pH | 862.1120 | II | CHL |
EasyQC BGEM Material for EasyStat
| Description | Regulation No. | Device Class | Product Code |
|---|---|---|---|
| Quality control Material | 862.1660 | Class I | JJY |
Predicate devices:
| Description | 510(k) | Regulation No. | Device Class | Product Code |
|---|---|---|---|---|
| EasyStat Blood Gas Analyzer | K021515 | 862.1120 | II | CHL |
{4}------------------------------------------------
Device Description and Indications for Use:
The EasyStat 300 is a system for use by health care professionals to rapidly analyze whole blood samples. Good Laboratory Practices (GLPs) are strongly advised when using the EasyStat 300. The analyzer incorporates a Reagent Module containing the "calibrating" solutions A2, B2, and a "conditioning" solution C2, which is also use a calibrant for the Oxygen sensor. Calibrations are performed automatically or on-demand by the user to establish the "slope" of each sensor used in the calculation of the patient sample.
The EasyStat 300 uses 175μL of whole blood in the "Syringe" mode and 100μL of whole blood in the "Capillary" mode to analyze patient samples. Medica provides a capillary tube kit (REF 8303) used for the capillary data collection in this submission. The EasyStat 300 reports results for blood Gases (PCO2, PO2), and pH. Additionally, it provides a number of calculated parameters based on the reported results and a number of input parameters as described in the Operator's Manual.
The EasyStat 300 is a microprocessor-controlled device with a touch sensitive screen that guides the operator through the different menu options and proper operation. It also incorporates a thermal printer to record all reported results and patient information as described in the Operator's Manual. The device software has incorporated routines to assist the end-user with maintenance, cleaning, and troubleshooting activities also outlined in the manual. The incorporated USB port may be used to download data and also to update the software version based on detailed instructions by Medica Corporation.
The blood gas and pH sensors require calibration and cleaning after a predefined number of samples are analyzed as described in the Operator's Manual. The pH and PCO2 sensors are based on potentiometric sensor design, generating a small voltage that is dependent on the concentrations of these analytes in the patient sample. The PO2 sensor is based on amperometric sensor design that generates a small current that is dependent on the concentration of oxygen in the patient sample. The theory and mathematical formulas on which the sensor functionality is based are described in the Operator's Manual.
Medica's EasyQC materials (REF 8315/8316/8317 and 8309) are specifically formulated for the EasyStat 300. Medica requires the use of quality controls everyday patient samples are analyzed and after any troubleshooting is performed, as instructed in the Operator's Manual, to validate the performance of the analyzer. The analyzer stores QC results and provides a statistical analysis of its performance using Levey-Jennings plots for the last 30 consecutive days. The EasyQC materials for the EasyStat 300 have a minimum of three years shelf-life when stored refrigerated (20-80C).
The Reagent Module (REF 8101) has a twelve-month shelf-life when stored at 4º-25ºC. Use-life depends on the number of samples analyzed and the overall performance of the sensors. The analyzer monitors the consumption of calibrant solution A2 and warns the operator when the reagent module is about to expire. A typical Use-life for an average user is expected to be 15
{5}------------------------------------------------
days and/or 350 samples whichever comes first. This feature is the one provided with the predicate EasyStat analyzer.
The sensors have one-year shelf-life when stored at 4º 25ºC for blood gases (PCO2, PO2), pH. Use-Life of the sensors is determined from their calibration profiles and from the reported results during the EasyQC analysis. Sensors are replaced by the operator as described in the Operator's Manual. An automatic calibration is performed after installation to qualify the new sensor(s) and the operator is instructed to use the EasyQC multi-level QC materials to validate the EasyStat 300 performance.
The EasyStat 300 may be equipped with a Medica provided barcode scanner (REF 8420) via a USB port to automatically enter patient sample and EasyQC material info. Details are provided in the operator's Manual.
To maintain the performance of the analyzer Medica provides a cleaning solution (REF 8305) and a troubleshooting kit (REF 8250). Their proper uses are described also in the operator's Manual.
Intended use and Indications for use of the analytes measured by the EasyStat 300 are:
The EasyStat 300 provides quantitative measurements of pH (hydrogen ion activity), pCO2 (partial pressure of carbon dioxide), and pO2 (partial pressure of oxygen) in Li-heparinized whole blood (arterial/venous) samples from Syringes or Capillary Tubes. This Analyzer should only be used by trained technicians in clinical laboratories to aid in the diagnosis and treatment of patients with blood gas and/or acid-base disturbances.
pCO2, PO2 (blood gases) and pH measurements in blood are used in the diagnosis and treatment of lifethreatening acid-base disturbances.
The EasyStat 300 has the same technical characteristics with the predicate device. Sensor technology, Reagent module calibrating solutions, principles of operation, and parameters measured are practically the same. User device display may differ due to the new touch sensitive screen, user menu preferences, and more friendly user interface. None of these differences affect the performance when compared to the predicate EasyStat analyzer. The following sections provide a brief discussion of the performance characteristics of the EasyStat 300 based on the studies submitted to determine substantial equivalency.
All tests on the following sections are non-clinical bench tests except for Method Comparison, which was performed on a clinical laboratory using actual venous and arterial blood. The non-clinical tests also used contrived venous blood of aqueous QC materials that are part of the EasyStat 300 system.
{6}------------------------------------------------
| EasyStat 300 | EasyStat Ca++ | |
|---|---|---|
| 510(k) Number | New IVD Device | K021515 |
| Manufacturer | Medica Corp. | Medica Corp. |
| Address | 5 Oak Park Dr. Bedford, MA 01730 | 5 Oak Park Dr. Bedford, MA 01730 |
| Intended Use | Clinical Laboratories | Clinical Laboratories |
| Indications for Use | Same with predicate devices | Same with submitted device |
| Operating Principle | Potentiometric | Potentiometric |
| pH | Potentiometric | Potentiometric |
| PCO2 | Potentiometric | Potentiometric |
| PO2 | Amperometric | Amperometric |
| Calibrant Base | Aqueous | Aqueous |
| Measured Parameters | pH, pCO2, pO2 | pH, PCO2, PO2 |
| Sample Type | Whole Blood | Whole Blood |
| Sample Volume | 175µL Syringe, 100 µL Capillary | 120µL Syringe, 95 µL Capillary |
| Analysis Time | 110 seconds | 120 seconds |
| Measured Range | ||
| pH | 6.800 to 8.000 units | 6.500 to 8.000 units |
| pCO2 | 5.0 – 150.0 mmHg | 5.0 – 150.0 mmHg |
| pO2 | 5-700 mHg | 5-700 mmHg |
| Display | TFT LCD, Touch screen | LCD |
| Printer | Thermal | Thermal |
| Communication Ports | USB (5), 1 for Barcode reader | None |
| Ethernet (1) | None | |
| RS232 Serial (1) | RS232 Serial (1) | |
| SD card port (1) | None | |
| N/A | Barcode Reader | |
| Calculated Parameters | Patient Temp. Correction, pH, PCO2, PO2 | Patient Temp. Correction, pH, PCO2, O2 |
| Total Hemoglobin | Total Hemoglobin | |
| Hematocrit, measured | Hematocrit, measured | |
| Total CO2 (TCO2) | Total CO2 (TCO2) | |
| Bicarbonate (HCO3-) | Bicarbonate (HCO3-) | |
| Base excess of blood (BEb) | Base excess of blood (BEb) | |
| Base excess of Extracellular fluid (BEecf) | Base excess of Extracellular fluid (BEecf) | |
| Standard Bicarbonate (SBC) | Standard Bicarbonate (SBC) | |
| Oxygen Saturation calculated at P50 (%SO2c) | Oxygen Saturation calculated at P50 (%SO2c) | |
| Total Oxygen Content (ctO2) | Total Oxygen Content (ctO2) | |
| Alveolar-Arterial O2 Gradient (A-aDO2) | Alveolar-Arterial O2 Gradient (A-aDO2) | |
| Respiratory Index (RI) | Respiratory Index (RI) | |
| Safety Compliance | EN61010 | EN61010 |
| EMC Compliance | EN55011 | EN55011 |
| UL Tested | UL3101 | UL3101 |
| CSA Tested | C22.2 | C22.2 |
| Dimensions | 14.5"WX13"HX7"D | 14.25"W X 12.5"H X 7"D |
| Voltage Requirements | 110/115VAC, 50-60Hz, 220VAC, 50-60Hz | 110/115VAC, 50-60Hz, 220VAC, 50-60Hz |
Substantial Equivalency Between EasyStat 300 and predicate EasyStat
{7}------------------------------------------------
All tests on the following sections are non-clinical bench tests except for Method Comparison, which was performed on a clinical laboratory using actual venous and arterial blood. The non-clinical tests also used contrived venous blood of aqueous QC materials that are part of the EasyStat 300 system.
{8}------------------------------------------------
Performance Summaries:
Precision Studies:
Repeatability 20-Day Precision Study (Syringe & Capillary Modes) – Aqueous Controls
Medica used the EasyStat 300 tri-level aqueous EasyQC material to establish the Total and Within-Run precision of all analytes reported by the EasyStat 300. Each of the quality control levels were analyzed in three EasyStat 300 analyzers for twenty days taking duplicate readings in the morning (AM) and afternoon (PM). All results were within specification.
| PrecisionEstimate | Level | Target | PerformanceSpecs | System 1_P21 | System 2_P22 | System 3_P23 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SD | CV | Mean | SD | CV | Mean | SD | CV | Mean | SD | CV | ||||
| PO2 | Within-Device(Total) | 1 | 36 | 2.5 | 36 | 1.39 | 35 | 1.33 | 37 | 1.18 | ||||
| 2 | 98 | 2.5 | 99 | 1.61 | 98 | 2.23 | 99 | 1.56 | ||||||
| 3 | 136 | 2.5% | 137 | 1.4 | 137 | 1.4 | 138 | 1.5 | ||||||
| PCO2 | Within-Device(Total) | 1 | 69.0 | 5.0% | 68.9 | 0.9 | 68.1 | 0.9 | 68.3 | 0.8 | ||||
| 2 | 45.0 | 4.0% | 45.4 | 1.2 | 45.2 | 1.0 | 45.2 | 0.9 | ||||||
| 3 | 21.0 | 2.0 | 21.2 | 0.28 | 21.4 | 1.13 | 21.1 | 0.23 | ||||||
| pH | Within-Device(Total) | 1 | 7.186 | 0.020 | 7.183 | 0.002 | 7.182 | 0.002 | 7.185 | 0.001 | ||||
| 2 | 7.411 | 0.015 | 7.410 | 0.002 | 7.410 | 0.003 | 7.408 | 0.002 | ||||||
| 3 | 7.621 | 0.020 | 7.622 | 0.004 | 7.623 | 0.002 | 7.618 | 0.002 |
Typical Repeatability Precision Study (Syringe Mode) – Aqueous Controls
Typical Repeatability Precision Study (Capillary Mode) – Aqueous Controls
| 20 Day QC Precision (Capillary Mode) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyte | PrecisionEstimate | Level | Target | PerformanceSpecs | Unit 1 | Unit 2 | Unit 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SD | CV | Mean | SD | CV | Mean | SD | CV | Mean | SD | CV | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PO2 | Repeatability(Within-Run) | 1 | 36 | 3 | 53 | 2.70 | 5.1 | 53 | 1.70 | 3.2 | 52 | 2.41 | 4.6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | 98 | 3 | 107 | 1.51 | 1.4 | 108 | 1.84 | 1.7 | 108 | 1.99 | 1.8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | 136 | 3.0% | 140 | 1.85 | 1.3 | 140 | 1.52 | 1.1 | 141 | 2.50 | 1.8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PO2 | Within-Device(Total) | 1 | 36 | 4 | 53 | 3.67 | 7.0 | 53 | 2.81 | 5.3 | 52 | 4.00 | 7.7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | 98 | 4 | 107 | 2.49 | 2.3 | 108 | 2.37 | 2.2 | 108 | 2.25 | 2.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | 136 | 4.0% | 140 | 2.30 | 1.6 | 140 | 3.17 | 2.3 | 141 | 2.72 | 1.9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PCO2 | Repeatability(Within-Run) | 1 | 69.0 | 5.0% | 63.4 | 0.96 | 1.5 | 63.0 | 0.93 | 1.5 | 63.2 | 0.68 | 1.1 | 2 | 45.0 | 4.0% | 41.4 | 0.45 | 1.1 | 41.1 | 0.50 | 1.2 | 41.2 | 0.42 | 1.0 | 3 | 21.0 | 1.5 | 21.2 | 0.19 | 0.9 | 21.4 | 0.21 | 1.0 | 21.2 | 0.23 | 1.1 | PCO2 | Within-Device(Total) | 1 | 69.0 | 5.0% | 63.4 | 1.14 | 1.8 | 63.0 | 1.15 | 1.8 | 63.2 | 1.00 | 1.6 | 2 | 45.0 | 4.0% | 41.4 | 0.52 | 1.3 | 41.1 | 0.55 | 1.3 | 41.2 | 0.46 | 1.1 | 3 | 21.0 | 2.0 | 21.2 | 0.23 | 1.1 | 21.4 | 0.27 | 1.3 | 21.2 | 0.25 | 1.2 | pH | Repeatability(Within-Run) | 1 | 7.186 | 0.020 | 7.209 | 0.004 | 0.06 | 7.192 | 0.006 | 0.08 | 7.197 | 0.007 | 0.09 | 2 | 7.411 | 0.015 | 7.433 | 0.003 | 0.04 | 7.421 | 0.003 | 0.04 | 7.423 | 0.002 | 0.03 | 3 | 7.621 | 0.020 | 7.619 | 0.004 | 0.05 | 7.612 | 0.003 | 0.03 | 7.609 | 0.003 | 0.04 | pH | Within-Device(Total) | 1 | 7.186 | 0.020 | 7.209 | 0.011 | 0.16 | 7.192 | 0.008 | 0.10 | 7.197 | 0.011 | 0.16 | 2 | 7.411 | 0.015 | 7.433 | 0.009 | 0.12 | 7.421 | 0.003 | 0.04 | 7.423 | 0.005 | 0.06 | 3 | 7.621 | 0.020 | 7.619 | 0.007 | 0.10 | 7.612 | 0.004 | 0.05 | 7.609 | 0.004 | 0.06 | ||||||||||||||||||||
| PCO2 | Repeatability(Within-Run) | 1 | 69.0 | 5.0% | 63.4 | 0.96 | 1.5 | 63.0 | 0.93 | 1.5 | 63.2 | 0.68 | 1.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | 45.0 | 4.0% | 41.4 | 0.45 | 1.1 | 41.1 | 0.50 | 1.2 | 41.2 | 0.42 | 1.0 | 3 | 21.0 | 1.5 | 21.2 | 0.19 | 0.9 | 21.4 | 0.21 | 1.0 | 21.2 | 0.23 | 1.1 | PCO2 | Within-Device(Total) | 1 | 69.0 | 5.0% | 63.4 | 1.14 | 1.8 | 63.0 | 1.15 | 1.8 | 63.2 | 1.00 | 1.6 | 2 | 45.0 | 4.0% | 41.4 | 0.52 | 1.3 | 41.1 | 0.55 | 1.3 | 41.2 | 0.46 | 1.1 | 3 | 21.0 | 2.0 | 21.2 | 0.23 | 1.1 | 21.4 | 0.27 | 1.3 | 21.2 | 0.25 | 1.2 | pH | Repeatability(Within-Run) | 1 | 7.186 | 0.020 | 7.209 | 0.004 | 0.06 | 7.192 | 0.006 | 0.08 | 7.197 | 0.007 | 0.09 | 2 | 7.411 | 0.015 | 7.433 | 0.003 | 0.04 | 7.421 | 0.003 | 0.04 | 7.423 | 0.002 | 0.03 | 3 | 7.621 | 0.020 | 7.619 | 0.004 | 0.05 | 7.612 | 0.003 | 0.03 | 7.609 | 0.003 | 0.04 | pH | Within-Device(Total) | 1 | 7.186 | 0.020 | 7.209 | 0.011 | 0.16 | 7.192 | 0.008 | 0.10 | 7.197 | 0.011 | 0.16 | 2 | 7.411 | 0.015 | 7.433 | 0.009 | 0.12 | 7.421 | 0.003 | 0.04 | 7.423 | 0.005 | 0.06 | 3 | 7.621 | 0.020 | 7.619 | 0.007 | 0.10 | 7.612 | 0.004 | 0.05 | 7.609 | 0.004 | 0.06 | ||||||||||||||||||||||||||||||||||
| 2 | 45.0 | 4.0% | 41.4 | 0.45 | 1.1 | 41.1 | 0.50 | 1.2 | 41.2 | 0.42 | 1.0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | 21.0 | 1.5 | 21.2 | 0.19 | 0.9 | 21.4 | 0.21 | 1.0 | 21.2 | 0.23 | 1.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PCO2 | Within-Device(Total) | 1 | 69.0 | 5.0% | 63.4 | 1.14 | 1.8 | 63.0 | 1.15 | 1.8 | 63.2 | 1.00 | 1.6 | 2 | 45.0 | 4.0% | 41.4 | 0.52 | 1.3 | 41.1 | 0.55 | 1.3 | 41.2 | 0.46 | 1.1 | 3 | 21.0 | 2.0 | 21.2 | 0.23 | 1.1 | 21.4 | 0.27 | 1.3 | 21.2 | 0.25 | 1.2 | pH | Repeatability(Within-Run) | 1 | 7.186 | 0.020 | 7.209 | 0.004 | 0.06 | 7.192 | 0.006 | 0.08 | 7.197 | 0.007 | 0.09 | 2 | 7.411 | 0.015 | 7.433 | 0.003 | 0.04 | 7.421 | 0.003 | 0.04 | 7.423 | 0.002 | 0.03 | 3 | 7.621 | 0.020 | 7.619 | 0.004 | 0.05 | 7.612 | 0.003 | 0.03 | 7.609 | 0.003 | 0.04 | pH | Within-Device(Total) | 1 | 7.186 | 0.020 | 7.209 | 0.011 | 0.16 | 7.192 | 0.008 | 0.10 | 7.197 | 0.011 | 0.16 | 2 | 7.411 | 0.015 | 7.433 | 0.009 | 0.12 | 7.421 | 0.003 | 0.04 | 7.423 | 0.005 | 0.06 | 3 | 7.621 | 0.020 | 7.619 | 0.007 | 0.10 | 7.612 | 0.004 | 0.05 | 7.609 | 0.004 | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PCO2 | Within-Device(Total) | 1 | 69.0 | 5.0% | 63.4 | 1.14 | 1.8 | 63.0 | 1.15 | 1.8 | 63.2 | 1.00 | 1.6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | 45.0 | 4.0% | 41.4 | 0.52 | 1.3 | 41.1 | 0.55 | 1.3 | 41.2 | 0.46 | 1.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | 21.0 | 2.0 | 21.2 | 0.23 | 1.1 | 21.4 | 0.27 | 1.3 | 21.2 | 0.25 | 1.2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| pH | Repeatability(Within-Run) | 1 | 7.186 | 0.020 | 7.209 | 0.004 | 0.06 | 7.192 | 0.006 | 0.08 | 7.197 | 0.007 | 0.09 | 2 | 7.411 | 0.015 | 7.433 | 0.003 | 0.04 | 7.421 | 0.003 | 0.04 | 7.423 | 0.002 | 0.03 | 3 | 7.621 | 0.020 | 7.619 | 0.004 | 0.05 | 7.612 | 0.003 | 0.03 | 7.609 | 0.003 | 0.04 | pH | Within-Device(Total) | 1 | 7.186 | 0.020 | 7.209 | 0.011 | 0.16 | 7.192 | 0.008 | 0.10 | 7.197 | 0.011 | 0.16 | 2 | 7.411 | 0.015 | 7.433 | 0.009 | 0.12 | 7.421 | 0.003 | 0.04 | 7.423 | 0.005 | 0.06 | 3 | 7.621 | 0.020 | 7.619 | 0.007 | 0.10 | 7.612 | 0.004 | 0.05 | 7.609 | 0.004 | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| pH | Repeatability(Within-Run) | 1 | 7.186 | 0.020 | 7.209 | 0.004 | 0.06 | 7.192 | 0.006 | 0.08 | 7.197 | 0.007 | 0.09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | 7.411 | 0.015 | 7.433 | 0.003 | 0.04 | 7.421 | 0.003 | 0.04 | 7.423 | 0.002 | 0.03 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | 7.621 | 0.020 | 7.619 | 0.004 | 0.05 | 7.612 | 0.003 | 0.03 | 7.609 | 0.003 | 0.04 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| pH | Within-Device(Total) | 1 | 7.186 | 0.020 | 7.209 | 0.011 | 0.16 | 7.192 | 0.008 | 0.10 | 7.197 | 0.011 | 0.16 | 2 | 7.411 | 0.015 | 7.433 | 0.009 | 0.12 | 7.421 | 0.003 | 0.04 | 7.423 | 0.005 | 0.06 | 3 | 7.621 | 0.020 | 7.619 | 0.007 | 0.10 | 7.612 | 0.004 | 0.05 | 7.609 | 0.004 | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| pH | Within-Device(Total) | 1 | 7.186 | 0.020 | 7.209 | 0.011 | 0.16 | 7.192 | 0.008 | 0.10 | 7.197 | 0.011 | 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | 7.411 | 0.015 | 7.433 | 0.009 | 0.12 | 7.421 | 0.003 | 0.04 | 7.423 | 0.005 | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | 7.621 | 0.020 | 7.619 | 0.007 | 0.10 | 7.612 | 0.004 | 0.05 | 7.609 | 0.004 | 0.06 |
{9}------------------------------------------------
Reproducibility (5-Day) Precision Study - Syringe & Capillary Modes
This study was performed as a substitute to the typical single run with twenty whole blood replicates. We chose to use the option allowed in the CLSI EP05-A3 protocol to run five replicates of whole blood for five days. All results were within specification.
| Within-Run, 5-day w. Blood Study | |||||
|---|---|---|---|---|---|
| Analyte | Metric | Level 1 | Level 2 | Level 3 | |
| Avg (mmHg) | 39 | 78 | 223 | ||
| PO2 | SD (mmHg) | 0.6 | 1.7 | 3.3 | |
| CV(%) | 1.5 | 2.1 | 1.5 | ||
| specification | 2.5mmHg | 2.5mmHg | 3.0% | ||
| Avg (mmHg) | 36.9 | 67.4 | 132.6 | ||
| PCO2 | SD (mmHg) | 0.5 | 1.3 | 2.7 | |
| CV(%) | 1.3 | 1.9 | 2.1 | ||
| specification | 2.0% | 3.0% | 3.0% | ||
| Avg (pH units) | 7.410 | 7.216 | 7.588 | ||
| pH | SD (pH units) | 0.007 | 0.010 | 0.007 | |
| CV(%) | 0.1 | 0.1 | 0.1 | ||
| specification | 0.015 units | 0.015 units | 0.015 units |
Typical Repeatability Performance of the EasyStat 300 operating in "Syringe" mode
Typical Reproducibility Performance of the EasyStat 300 operating in "Capillary" mode
| Within-Run, 5-day w. Blood Study | ||||
|---|---|---|---|---|
| Analyte | Metric | Level 1 | Level 2 | Level 3 |
| PO2 | Avg (mmHg) | 39.7 | 80.8 | 225.2 |
| SD (mmHg) | 0.9 | 1.1 | 2.2 | |
| CV(%) | 2.3 | 1.4 | 1 | |
| specification | 2.4mmHg | 3.0% | 3.0% | |
| PCO2 | Avg (mmHg) | 36.0 | 65.9 | 131.1 |
| SD (mmHg) | 0.91 | 1.91 | 2.62 | |
| CV(%) | 2.5 | 2.9 | 2 | |
| specification | 4.0% | 5.0% | 5.0% | |
| pH | Avg (pH units) | 7.409 | 7.218 | 7.561 |
| SD (pH units) | 0.008 | 0.011 | 0.006 | |
| CV(%) | 0.1 | 0.1 | 0.1 | |
| specification | 0.015 units | 0.015 units | 0.015 units |
Conclusion of Precision Studies
Medica's Total precision and Within-Run precision studies, demonstrate that the EasyStat 300 Blood-Gas/Electrolyte/metabolite analyzer is precise and true to Medica's performance specifications and comparable to the predicate device in this submission.
{10}------------------------------------------------
Linearity Study
This study followed the CLSI EP06-A protocol officially recognized by the FDA. The linearity performance on the EasyStat 300 was evaluated using nine (9) to eleven (11) spiked and diluted whole blood specimens to cover the reportable range for each analyte. The pre-assayed whole blood samples were finally tested in triplicate on three EasyStat 300 analyzers to establish the linearity performance for each analyte. The table below shows a summary of the obtained results that met all device specifications.
| Linearity Summary for one of the three EasyStat 300 analyzers operating in the "Syringe" mode | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Analyte | Date | Predicate | ES300 | Syringe | ||||||
| Sensor 1 | Sensor 2 | |||||||||
| Linearity | Slope | R2 | Linearity | Slope | R2 | |||||
| PO2 | 12/26/19 | ES_4 | P7 | PASS | 1.016 | 0.999 | ||||
| P8 | PASS | 1.027 | 0.998 | |||||||
| P17 | PASS | 1.013 | 0.999 | |||||||
| PCO2 | 12/26/19 | ES_3 | P7 | PASS | 1.066 | 0.999 | ||||
| P8 | PASS | 0.984 | 0.998 | |||||||
| P17 | PASS | 0.983 | 0.996 | |||||||
| pH | 01/22/20 | ES_4 | P7 | PASS | 1.008 | 0.996 | PASS | 1.011 | 0.996 | |
| P8 | PASS | 1.022 | 0.997 | PASS | 0.981 | 0.997 | ||||
| P17 | PASS | 1.027 | 0.997 | PASS | 1.061 | 0.997 |
Conclusion of Linearity Study
Data from the linearity study on three EasyStat 300 analyzers performed according to CLSI EP6-A demonstrate that all analytes (pH, pCO2, pO2) reported by the EasyStat 300 are linear within the advertised reportable range.
{11}------------------------------------------------
Method Comparison Study
This study followed the CLSI EP9-A2 protocol. For this study we used whole blood from more than 200 donors plus six modified whole blood samples (spiked and diluted). All blood samples were tested on the predicate devices twice and on three EasyStat 300 analyzers. Some samples were modified to achieve analyte levels covering the reportable range using tonometry.
In addition, the "Capillary" mode on The EasyStat 300 was evaluated against the "Capillary" mode on the predicate EasyStat analyzer using the same whole blood samples collected with the same capillary tubes.
Conclusion of the Method Comparison Study
Data from the Method Comparison study on three EasyStat 300 analyzers demonstrate that all analytes (pH, pCO2, pO2) reported by the EasyStat 300 are favorably correlated to the predicate/reference device selected for this study. For all analytes (pH, pCO2, pO2), the linear regression slope, the coefficient of variation, and the calculated predicted bias at the decision levels for each analyte were within specifications.
Typical correlation results for all analytes (pO2, pCO2, pH) are shown below:
{12}------------------------------------------------
Image /page/12/Figure/1 description: This image contains four scatter plots comparing PO2 measurements using different methods (Syringe vs. Capillary) and their corresponding absolute differences. The top two plots show linear regressions, while the bottom two display absolute differences between ES300 PO2 and EasyStat PO2. Each method includes a table summarizing statistical parameters such as 'n', slope, intercept, R-squared, standard error, predicted bias, 95% confidence interval, 100% total allowable error, and status for MDL values of 30, 45, and 60. The Syringe method has a sample size of 272, while the Capillary method has a sample size of 224.
pO2 Method Comparison Analysis (Syringe & Capillary Modes)
{13}------------------------------------------------
Image /page/13/Figure/1 description: The image shows two scatter plots and a table comparing PCO2 measurement methods using a syringe. The first scatter plot, titled "PCO2 Method Comparison (Syringe), Linear Regression", plots ES300 PCO2 (Rep 1) against EasyStat PCO2 (Avg), with a linear regression line. The second scatter plot, titled "PCO2 Method Comparison (Syringe), Absolute Difference", plots the difference between ES300 PCO2 (Rep 1) and EasyStat PCO2 (Avg) against EasyStat PCO2 (Avg). The table provides statistical data, including n=265, Slope=1.040, Intercept=-1.159, R^2=0.992, and Std Error=1.326, as well as predicted bias, confidence intervals, allowable errors, and status for MDL values of 5.0, 62.5, and 150.0, all of which PASS.
pCO2 Method Comparison Analysis (Syringe & Capillary Modes)
Image /page/13/Figure/3 description: The image contains two scatter plots comparing PCO2 measurement methods using capillary samples. The first plot, titled "PCO2 Method Comparison (Capillary), Linear Regression," shows a linear regression analysis with EasyStat PCO2 (Avg) on the x-axis and ES300 PCO2 (Rep 1) on the y-axis. The second plot, titled "PCO2 Method Comparison (Capillary), Absolute Difference," displays the absolute difference between the two methods against EasyStat PCO2 (Avg). The image also includes a table with statistical parameters such as n=219, Slope=0.943, Intercept=2.624, R^2=0.911, and Std Error=1.946.
Min
7.0
61.3
143.3
2.34
-0.94
-5.93
5.0
62.5
150.0
Max
7.6
61.8
144.8
Min
0.0
57.5
138.0
Max
10.0
67.5
162.0
PASS
PASS
PASS
510(k) Summary, K211559/S001
{14}------------------------------------------------
Image /page/14/Figure/1 description: The image shows a pH method comparison between a syringe and a capillary. There are four scatter plots in the image. The top two plots show a linear regression between the two methods, while the bottom two plots show the absolute difference between the two methods. There are also tables that show the slope, intercept, R^2, and standard error for each method, as well as the predicted bias, 95% confidence interval, and 100% total allowable error.
pH Method Comparison Analysis (Syringe & Capillary Modes)
{15}------------------------------------------------
Sensitivity
The sensitivity study is used to validate the low end of the Reportable Range for a particular assay on the EasyStat 300. The study first establishes the Limit of Blank (LoB) that is the starting point for determining the Limit of Detection (LoD) and subsequently the Limit of Quantitation (LoQ).
The sensitivity study in this submission followed the guidelines from CLSI EP17-A. It was performed on three ES 300 analyzers covering the pH and blood gas sensors.
The following table lists the measured LoB, LoD, and LoQ for all analytes reported by the EasyStat 300 analyzer.
| Analyte | Type of sample used | LoB | LoD | LoQ | Lowest Detection Limit (LDL) | LoQ < LDL? |
|---|---|---|---|---|---|---|
| pO2 | Tonometered w. Blood | 3 mmHg | 4 mmHg | 4 mmHg | 5 mmHg | Yes |
| pCO2 | Tonometered w. Blood | 2.8 mmHg | 4.6 mmHg | 4.6 mmHg | 5.0 mmHg | Yes |
| pH | Buffered Saline | 6.140 pH units | 6.498 pH units | 6.498 pH units | 6.800 pH units | Yes |
Conclusion of the Sensitivity Study
The lower reportable limit for each assay on the EasyStat 300 was based on the LoQ result calculated or experimentally determined in this sensitivity studies indicate that the following values may be used as the lowest limit of the reportable range of each assay available on the EasyStat 300.
p02: 5 mmHg pCO2: 5.0 mmHg 6.800 units pH
{16}------------------------------------------------
Selectivity
The selectivity (interference) study has followed in principle the guidelines from CLSI EP07-A. The level chosen is the typical normal value for a particular analyte in whole blood. All collected data are from spiked whole blood samples collected from healthy donors.
| Interference | Test Level | Gas/pHLevel | pO2 | pCO2 | pH | ||||
|---|---|---|---|---|---|---|---|---|---|
| Change, mmHg | %Change | Change, mmHg | %Change | Change, pH Units | Conclusion | ||||
| 1 | Acetaminophen | 15.6 mg/dL | A | 1.7 | 6.7 | 0.6 | 1.6 | 0.009 | No Interference |
| B | 5.3 | 3.1 | 2.1 | 2.3 | 0.001 | No Interference | |||
| 2 | Albumin(Protein) | 60 g/L | A | -0.3 | -0.55 | 0.4 | 1.2 | 0.029 | No Interference |
| B | 3.3 | 2.1 | 1.0 | 1.1 | 0.027 | No Interference | |||
| 3 | Amoxicillin | 0.206 mM | A | -0.3 | -1.3 | 0.3 | 0.9 | -0.005 | No Interference |
| B | -1.7 | -1.1 | 1.2 | 1.4 | 0.006 | No Interference | |||
| 4 | Aprotinin | 50 mg/L | A | -1.00 | -1.91 | -0.3 | -0.7 | 0.007 | No Interference |
| B | 1.3 | 0.8 | 0.2 | 0.3 | 0.003 | No Interference | |||
| 5 | Atracurium | 50 mg/L | A | 0.0 | 0.0 | -0.2 | -0.7 | 0.016 | No Interference |
| B | 1.3 | 0.8 | 0.4 | 0.4 | 0.001 | No Interference | |||
| 6 | Benzalkoniumchloride | 5 mg/L | A | -0.3 | -1.4 | -0.3 | -0.8 | 0.006 | No Interference |
| B | 1.0 | 0.6 | -0.2 | -0.2 | 0.008 | No Interference | |||
| 7 | Bilirubin | 20 mg/dL | A | 0.7 | 2.6 | 0.3 | 0.9 | 0.000 | No Interference |
| B | -1.0 | -0.6 | -0.6 | -0.7 | 0.002 | No Interference | |||
| 8 | Ceftriaxone | 1.46 mM | A | 0.7 | 2.5 | 0.3 | 0.9 | -0.004 | No Interference |
| B | -2.0 | -1.2 | 2.4 | 2.5 | -0.002 | No Interference | |||
| 9 | Ciprofloxin | 30.2 μM | A | 1.0 | 3.8 | 0.4 | 1.0 | -0.002 | No Interference |
| B | 0.3 | 0.2 | -0.6 | -0.7 | 0.001 | No Interference | |||
| 10 | Epinephrine | 0.5 μM | A | 0.3 | 1.3 | 0.6 | 1.6 | -0.009 | No Interference |
| B | -4.7 | -3.2 | -1.9 | -2.2 | 0.007 | No Interference | |||
| 11 | Ethanol | 600 mg/dL | A | 1.00 | 1.69 | 1.1 | 3.0 | -0.011 | No Interference |
| B | 0.3 | 0.2 | 0.2 | 0.2 | 0.010 | No Interference | |||
| 12 | Gentamycin | 3 mg/dL | A | 0.0 | 0.0 | 0.07 | 0.2 | 0.007 | No Interference |
| B | 4.0 | 2.5 | 0.4 | 0.5 | 0.007 | No Interference | |||
| 13 | Halothane | 4 mM | A | -1.0 | -3.7 | -0.2 | -0.6 | 0.005 | No Interference |
| B | -1.0 | -0.6 | -0.5 | -0.5 | 0.026 | No Interference | |||
| 14 | Hematocrit | 25% | A | 0.7 | 2.7 | 0.6 | 1.7 | -0.033 | No Interference |
| B | 0.7 | 0.4 | -1.0 | -1.1 | 0.001 | No Interference | |||
| 15 | Hematocrit | 65% | A | 1.7 | 5.8 | -0.4 | -1.02 | -0.007 | No Interference |
| B | -1.3 | -0.8 | -3.5 | -4.0 | 0.04 | No Interference | |||
| 16 | Hemoglobin | 25% (2.5 g/dL) | A | -0.3 | -0.54 | 0.1 | 0.3 | -0.028 | No Interference |
| B | -1.0 | -0.6 | -0.7 | -0.8 | -0.026 | No Interference | |||
| 17 | Heparin | 100 kU/L | A | -0.3 | -1.4 | 0.4 | 1.0 | 0.035 | No Interference |
| B | 4.0 | 2.5 | 3.6 | 3.9 | 0.006 | No Interference | |||
| 18 | Lithium Chloride | 3.2 mM | A | 1.0 | 4.0 | 1.2 | 3.2 | -0.007 | No Interference |
| B | -1.3 | -0.8 | 0.3 | 0.3 | -0.025 | No Interference | |||
| 19 | Omeprazole | 0.9 mg/dL | A | 2 | 7.9 | 0.2 | 0.6 | -0.011 | No Interference |
| B | 1.3 | 0.9 | 0.7 | 0.8 | 0.005 | No Interference | |||
| 20 | Propofol | 270 μM | A | 1.7 | 6.3 | 1.3 | 3.6 | 0.015 | No Interference |
| B | 2.0 | 1.3 | 1.1 | 1.3 | -0.009 | No Interference | |||
| 21 | Suxamethonium | 68 μM | A | 1.0 | 3.9 | -0.2 | -0.5 | -0.006 | No Interference |
| B | 0.7 | 0.4 | -0.5 | -0.6 | 0.001 | No Interference | |||
| 22 | Thyroxine | 1.29 μM | A | 2.0 | 7.6 | 0.6 | 1.6 | -0.015 | No Interference |
| B | 2.7 | 1.7 | 1.6 | 1.7 | 0.008 | No Interference | |||
| 23 | Triglycerides | 2% | A | 0.7 | 2.7 | 1.1 | 3.0 | 0.022 | No Interference |
| B | -1.3 | -0.8 | 1.3 | 1.4 | 0.027 | No Interference |
Note: "No Interference" If <10% change
pCO₂ 5% / pO₂ 3% → {pH ~7.48, PCO₂ ~37 mmHg, PO₂ ~23 mmHg} Level A:
pCO₂ 12% / pO₂ 20% → {pH ~7.19, PCO₂ ~90 mmHg, PO₂ ~143 mmHg} Level B:
{17}------------------------------------------------
Conclusion:
The technological and functional characteristics of the new EasyStat 300 analyzer described in the 510(k) summary are substantially equivalent to that of the predicate device EasyStat for pH, pCO2, and pO2.
The analytical study results demonstrate the EasyStat 300 is safe and effective for its intended purpose and equivalent in performance to the predicate device.
§ 862.1120 Blood gases (P
CO2 , PO2 ) and blood pH test system.(a)
Identification. A blood gases (PCO2 , PO2 ) and blood pH test system is a device intended to measure certain gases in blood, serum, plasma or pH of blood, serum, and plasma. Measurements of blood gases (PCO2 , PO2 ) and blood pH are used in the diagnosis and treatment of life-threatening acid-base disturbances.(b)
Classification. Class II.